Wall Street analysts expect that VIVUS, Inc. (NASDAQ:VVUS) will report earnings of ($1.10) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 83.3%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 6th.
On average, analysts expect that VIVUS will report full-year earnings of ($4.40) per share for the current financial year. For the next financial year, analysts expect that the firm will post earnings of ($5.70) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow VIVUS.
VIVUS (NASDAQ:VVUS) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.08). The firm had revenue of $14.96 million during the quarter.
A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC grew its holdings in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,273,800 shares of the biopharmaceutical company’s stock after buying an additional 423,100 shares during the period. Renaissance Technologies LLC owned 7.79% of VIVUS worth $5,833,000 at the end of the most recent quarter.
Shares of VVUS traded down $0.05 during mid-day trading on Friday, reaching $4.34. The company’s stock had a trading volume of 65,839 shares, compared to its average volume of 91,005. VIVUS has a 1-year low of $3.30 and a 1-year high of $9.90. The stock has a market cap of $46.98 million, a price-to-earnings ratio of -1.49 and a beta of 0.58. The company has a quick ratio of 4.26, a current ratio of 4.93 and a debt-to-equity ratio of -10.60.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Featured Story: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.